自身造血干细胞移植治疗儿童晚期神经母细胞瘤临床报道

目的 　神经母细胞瘤是儿童常见的恶性肿瘤 ,即使通过化疗、放疗及手术等综合治疗 ,晚期患儿仍生存率极低。为提高治愈率 ,本中心对 1 1例晚期患儿进行了自身造血干细胞移植术。方法 　本组平均年龄 3 8岁 ( 2～ 6岁 ) ,平均体重 1 5 3kg( 1 1 6kg～ 2 0kg)。 2例为原发于胸腔的Ⅲ期患者 ,9例均为原发于腹腔伴有广泛骨髓转移的IV期患儿。虽然大剂量化疗及积极的手术治疗 ,4例患儿移植时原发肿瘤仍未完全清除 ,属带瘤移植。因对其中 2例未缓解患儿进行了两次移植 ,1 1例患儿共进行了 1 3例次移植。 3例次直接采集骨髓 ,另 1 0例次采用外周血造干细胞进行移植。为减少移植后复发 ,4例患儿采集物经CliniMACS进行了CD+3 4细胞分选的净化处理。所有患儿均采用VP1 6 +卡铂 +马法兰的预处理方案。结果　采集骨髓及外周血得到的单个核细胞分别为 ( 5 7± 0 9)× 1 0 8/kg和 ( 5 7± 1 0 )× 1 0 8/kg ,两者之间无显著性差异 (P >0 0 5) ,所有患儿移植后都获造血重建 ,中性粒细胞恢复至 0 5× 1 0 9/L的平均时间为 1 0 5± 5 7天 ,非输血依赖的血小板大于 2 0× 1 0 9/L的时间为 1 6 8±9 4天 ,血小板大于 50× 1 0 9/L的时间为 33 1± 2 0 1天 ,移植过程中平均输注红细胞2 2± 2 0单位 ( 0～ 8单位 )?     

自体骨髓单个核细胞移植治疗糖尿病性下肢缺血的临床观察

目的观察自体骨髓单个核细胞移植治疗糖尿病性下肢缺血的疗效。方法应用自体骨髓单个核细胞移植治疗20例22条糖尿病性下肢缺血。全部为2型糖尿病的下肢血管并发症。结果总的疼痛缓解率为85.0%,截肢3例(13.6%)。对缓解患者的冷、凉感觉,总有效率为100.0%。7例患者接受了下肢动脉造影显示有不同程度的新生侧支血管形成。踝部经皮氧分压测定显示绝大多数高于临床上截肢的最低临界值20mmHg(1mmHg=0.133kPa)。结论自体骨髓单个核细胞移植治疗糖尿病性下肢缺血是一种相对简单、安全、有效的方法。     

Impact of insurance payer and socioeconomic status on type of autologous breast reconstruction

IntroductionAutologous breast reconstruction has evolved from more morbid procedures that sacrificed the abdominal muscle (the TRAM or transverse rectus abdominus muscle flap) to “perforator” flaps. Commercial insurers recognized the higher technical demand of perforator flaps by creating procedural codes with higher professional fees. This study examined whether procedure code discrepancies between insurance payers disproportionally incentivize perforator flaps among the commercially insured.MethodsAutologous breast reconstructions identified from the National Inpatient Sample (NIS) were subdivided into microvascular perforator (85.74, 85.75, 85.76), microvascular TRAM (85.73), and pedicled TRAM flaps (85.72). Demographics, comorbidities and access to care were compared. A logistic regression comparing microvascular reconstructions only was used to identify predictors for perforator flap reconstruction.ResultsA total of 66,968 cases of autologous breast reconstruction were identified. Perforator flaps were more likely among the commercially insured (p < 0.001) and higher insurance quartiles (p < 0.001).When comparing microvascular reconstruction, perforator flaps were 1.72 (p < 0.001) times more likely among the commercially insured. As compared to the lowest income quartile, the fourth quartile had an odds ratio of 1.36 (p < 0.001) for perforator flap reconstruction.ConclusionThe presence of a separate perforator flap billing code among the commercially insured may be exacerbating existing socioeconomic disparities in breast cancer reconstruction.     

口腔埋伏牙自体移植的临床研究

目的 探讨埋伏牙、易位牙再植的方法和临床疗效.方法 选择埋伏或易位的上前牙18颗,微创拔出错位牙,修整牙槽窝,立即植入牙槽窝内,结扎固定.术后1、2、3、4、5、6、12个月复查再植牙的松动度、牙髓活力、X线片.结果 18颗牙再植术后6个月各项指标正常,临床效果满意.结论 埋伏牙或易位牙可通过拔牙再植的方法恢复正常的咬合关系和咀嚼功能.     

Clinical outcome after 36 months of treatment with injections of autologous blood for recurrent dislocation of the temporomandibular joint

We investigated the prognosis after three years of treatment for recurrent dislocation of the temporomandibular joint with autologous blood given intravenously in 21 patients with a mean (range) age 64 (17-92) years of whom 16 had coexisting systemic disease. The mean (range) follow up from the first injection was 64 (41-99) months. Eighteen patients had no recurrence during the first 36 months after their first injection, which showed that this minimally-invasive treatment was effective, particularly for those who had conditions that made a mouthpiece or operation unsuitable.     

Autologous Stem Cell Transplantation in Patients With Multiple Myeloma: An Activity-based Costing Analysis,Comparing a Total Inpatient Model Versus an Early Discharge Model

BackgroundActivity-based costing (ABC) was developed and advocated as a means of overcoming the systematic distortions of traditional cost accounting.Materials and MethodsWe calculated the cost of high-dose chemotherapy and autologous stem cell transplantation (ASCT) in patients with multiple myeloma using the ABC method, through 2 different care models: the total inpatient model (TIM) and the early-discharge outpatient model (EDOM) and compared this with the approved diagnosis related-groups (DRG) Italian tariffs.ResultsThe TIM and EDOM models involved a total cost of €28,615.15 and €16,499.43, respectively. In the TIM model, the phase with the greatest economic impact was the posttransplant (recovery and hematologic engraftment) with 36.4% of the total cost, whereas in the EDOM model, the phase with the greatest economic impact was the pretransplant (chemo-mobilization, apheresis procedure, cryopreservation, and storage) phase, with 60.4% of total expenses. In an analysis of each episode, the TIM model comprised a higher absorption than the EDOM. In particular, the posttransplant represented 36.4% of the total costs in the TIM and 17.7% in EDOM model, respectively. The estimated reduction in cost per patient using an EDOM model was over €12,115.72. The repayment of the DRG in Calabrian Region for the ASCT procedure is €59,806. Given the real cost of the transplant, the estimated cost saving per patient is €31,190.85 in the TIM model and €43,306.57 in the EDOM model.ConclusionIn conclusion, the actual repayment of the DRG does not correspond to the real cost of the ASCT procedure in Italy. Moreover, using the EDOM, the cost of ASCT is approximately the half of the TIM model.     

Optimal treatment strategies in myeloma: An argument against maintenance therapy after autologous stem cell transplantation

Despite continuing advancements in novel therapeutics for multiple myeloma (MM), high-dose therapy with autologous stem cell rescue continues to represent the standard approach to treat transplant-eligible, newly diagnosed patients. As the disease remains essentially incurable, and median progression-free survival (PFS) times after autologous transplant are measured in years and not decades, attempts to improve outcomes in the post-transplant setting have been extensive and commonly focused on a “maintenance” approach. Although multiple trials have demonstrated PFS advantages for a variety of maintenance strategies, it is our position that the potential risks outweigh the benefits of this approach and this should not be the standard of care outside of clinical trials.